SCHEMBL3837006

SCHEMBL3837006

Nc1n[nH]c(N)c1N=Nc1c(Br)cc(F)cc1Br

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.59
MEN1 O00255 7/20 0.59
KMT2A Q03164 7/20 0.59
GFER P55789 4/20 0.59
RAB9A P51151 3/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
GAA P10253 8/20 0.57
CCNE1 P24864 9/20 0.50
CDK2 P24941 9/20 0.50
CCNE2 O96020 7/20 0.50
CCNT1 O60563 4/20 0.50
CDK9 P50750 4/20 0.50
TDP1 Q9NUW8 2/20 0.50
CDK4 P11802 3/20 0.49
CCND1 P24385 3/20 0.49
CDK7 P50613 3/20 0.49
CCNH P51946 3/20 0.49
CDK1 P06493 2/20 0.49
CCNB1 P14635 2/20 0.49
NPC1 O15118 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3841006 0.92 MAPT (0.55) MAPTMEN1KMT2AGFERRAB9A
SCHEMBL3837458 0.86 CCNE1 (0.53) MAPTMEN1KMT2AGFERRAB9A
SCHEMBL3837186 0.83 MEN1 (0.60) MAPTMEN1KMT2AGFERRAB9A
SCHEMBL3837095 0.83 GAA (0.52) MAPTMEN1KMT2AGFERRAB9A
SCHEMBL3842346 0.83 MEN1 (0.60) MAPTMEN1KMT2AGFERRAB9A
SCHEMBL3837734 0.81 GAA (0.72) MAPTMEN1KMT2AGFERRAB9A
SCHEMBL3841291 0.80 GAA (0.56) MAPTMEN1KMT2AGFERRAB9A
SCHEMBL3839607 0.79 GAA (0.48) MAPTMEN1KMT2AGFERRAB9A
SCHEMBL3839898 0.79 GAA (0.52) MAPTMEN1KMT2AGFERRAB9A
SCHEMBL3837701 0.76 GAA (0.56) MAPTMEN1KMT2AGFERRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786779-B1 4-ARYLAZO-3,5-DIAMINO-PYRAZOLE COMPOUNDS AND USE THEREOF INST OF EX BOTANY OF THE ASCR (CZ) 2009-10-28 EP claimed
US-20080312238-A1 4-Arylazo-3,5-Diamino-Pyrazole Compounds and Use Thereof INSTITUTE OF EXPERIMENTAL BONTANY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC, V.V.I. (CZ) 2008-12-18 US claimed
EP-1786779-A1 4-ARYLAZO-3,5-DIAMINO-PYRAZOLE COMPOUNDS AND USE THEREOF INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) 2007-05-23 EP claimed
WO-2006024858-A1 4-ARYLAZO-3,5-DIAMINO-PYRAZOLE COMPOUNDS AND USE THEREOF INSTITUTE OF EXPERIMENTAL BOTANY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 2006-03-09 WO claimed
US-8357673-B2 4-arylazo-3,5-diamino-pyrazole compounds and use thereof UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2013-01-22 US disclosed
EP-1786779-B1 4-ARYLAZO-3,5-DIAMINO-PYRAZOLE COMPOUNDS AND USE THEREOF INST OF EX BOTANY OF THE ASCR (CZ) 2009-10-28 EP disclosed
US-20080312238-A1 4-Arylazo-3,5-Diamino-Pyrazole Compounds and Use Thereof INSTITUTE OF EXPERIMENTAL BONTANY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC, V.V.I. (CZ) 2008-12-18 US disclosed
EP-1786779-A1 4-ARYLAZO-3,5-DIAMINO-PYRAZOLE COMPOUNDS AND USE THEREOF INSTITUTE OF EXPERIMENTAL BOTANY ASCR (CZ) 2007-05-23 EP disclosed
WO-2006024858-A1 4-ARYLAZO-3,5-DIAMINO-PYRAZOLE COMPOUNDS AND USE THEREOF INSTITUTE OF EXPERIMENTAL BOTANY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312238-A1 4-Arylazo-3,5-Diamino-Pyrazole Compounds and Use Thereof CDK9, CDK3, CDK19 MAPT 207/4885MEN1 4080/4885KMT2A 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.